TD BUY $CKPT at 4.11, Supp 4.11 Resis 5.00 R22 HiLo 71% T1Y 18 strong_buy 1.3 fwdPE -4.8 DIV N/A #Checkpoint #stocks #trading #finance #market

2019-05-30
45 Views

TD BUY detected for CKPT (Checkpoint Therapeut) at the close price of 4.11 with a support level at 4.11 and a resistance at 5.00, providing an opportunity for a 22 % return. Trading at a 71 % level between the 52week High (5.20) and 52 week Low (1.50). The average analyst 1-year target price is 18.0 with an average strong_buy and a score of 1.3.

TD Buy
22 %
CKPT
4.11
Checkpoint Therapeut
HiLo
70.5 %
Support
4.11
Resistance
5.00
Target1Y
18.00
Rated
strong_buy
Score
1.3
52week high
5.20
52week low
1.50
50DMA
3.69
200DMA
3.23
10DMA
0.00
20DMA
0.00
100DMA
0.00
Volume
81991
AvgDayVol
77295
MarketCap
148636512
EBITDA
0
Revenue
3515000
PE
0.00
P2S
42.29
P2B
0.00
Dividend
0.00
Div Ex-Date

Further research links:

Marketwatch Yahoo Finance Google Finance StockTwits

You may be interested

#GoldenCross $G1A.DE at 26.67 R7  HiLo 54% none PE 47.9 DIV 3.21% #GEA GROUP  #DAX #Aktien #Boerse #stocks
Bull, Europe, Germany
13 views
Bull, Europe, Germany
13 views

#GoldenCross $G1A.DE at 26.67 R7 HiLo 54% none PE 47.9 DIV 3.21% #GEA GROUP #DAX #Aktien #Boerse #stocks

Andreas Aigner - 2019-09-19

Golden Cross detected for G1A.DE (GEA GROUP AG) at the close price of 26.67. Trading at a 54 % level…

TD SELL $DLG.L at 305.40, Supp 279.90 Resis 305.40 R9  HiLo 30% T1Y 380 none PE 9.8 DIV 7.01% #DIRECT LIN #UK #LSE #London #stocks #trading
Bear, Europe, Financial Services
9 views
Bear, Europe, Financial Services
9 views

TD SELL $DLG.L at 305.40, Supp 279.90 Resis 305.40 R9 HiLo 30% T1Y 380 none PE 9.8 DIV 7.01% #DIRECT LIN #UK #LSE #London #stocks #trading

Andreas Aigner - 2019-09-19

TD SELL detected for DLG.L (DIRECT LINE INSURANC) at the close price of 305.40 with a support level at 279.90…

Leave a Comment

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

We use Cookies to improve our Site. Your are agreeing to this by continuing to use our Site.